New Antiseptic Drug
Organization of Experimental Production of Different Marketable Forms Rent Forms of New Antiseptic Drug of Creation Detergents Group - of MYRAMYSTINE
Tech Area / Field
- BIO-IND/Industrial Biotechnology/Biotechnology
- MED-DRG/Drug Discovery/Medicine
3 Approved without Funding
JSC Biochimmash, Russia, Moscow
- NPO BioTechnologia, Russia, Moscow
Project summaryNew antiseptic drug - MYR/4MYSTINE (myramystamidopropyldemethylbenzene ammonium chloride) is manufactured at present in Russia in the limited amounts only as 0,01% water solution. However, the range of its possible application is significantly wider.
Preparation has an expressed antimicrobial effect in relation to gram-positive and gram-negative, aerobic and anaerobic, sporeforming and asporogenic bacteria, has antifungial effect to yeast-like fungi, dermathophytes, ascomycetes and other pathogenic fungi, destructively effects to pathogens transferring by sexual way - gonococcus, herpes virus, AIDS, treponema, trichomonosis, chlamydia. MYR/IMYSTINE decreases bacteria and fungi resistance to antibiotics, stimulates immune processes, enhances local protective reactions and tissue regeneration.
Preclinical tests showed its potential application as other drug forms: ointments, eye drops, aerosol for inhalation, myramystine glue and as desinfetious mean - 0, l % water or alcohol solution for surgery (treatment of operation field, surgeon hands and surgical instrument, treatment, etc.).
The project is prepared, taking into account recommendations, set forth in the report "Biotechnology. Key Capabilities and Commercial Requirements" from 09.06.95, performed by Orion Enterprises, Incorporated and Novecon Technologies L.P. under leadership of Dr. Q.Lomatsky.
Objective of the proposed project: development of experimental-large-scale technological process and creation of experimental bay on the production of different forms of new antiseptic drug of cation detergents group - of MYRAMYSTINE
Major goals of study in order to solve the problem are indicated:
- analysis of experience of experimental batches production of antiseptic drug and development of initial data for the partial reconstruction of the existing production premises;
- equipping of the premises under reconstruction with the account of rules of drug production organization;
- development of experimental-large-scale technological process and production of experimental batches of various marketable forms of myramystine preparation;
- providing of clinical trials and registration of pharmacopoeia articles for new preparations forms.
As a result of the project performance it will be developed experimental-1arge-scale technology and will be created experimental bay on the production of new forms of myramystine antiseptic preparation.
Commercial application of the project results is also confirmed by potential interest of such companies as: Advanced Tissue Sciences, Organogenesis, Biosurface Technology and Clonetics, shown in the report "Biotechnology. Key Capabilities and Commercial Requirements" from 09.06.95 (Par.3.1, p.20), performed by Orion Enterprises, Incorporated and Novecon Technologies L.P. under leadership of Dr. O.Lomatsky. Besides, direct interest to the creation of new forms of antiseptics was expressed by other foreign firms, including Japanese company "ISKRA Industry Co., Ltd.", Tokyo, Chuoku Nikhonbasi, 1-14-2.